- Adial Pharmaceuticals (NASDAQ:ADIL) announces Crown’s engagement to manage Adial’s Phase 3 clinical trial for AD04 for the treatment of alcohol use disorder (AUD).
- The FDA approved protocol for this Phase 3 clinical trial is a 24-week trial with 290 patients, expected to begin in H1 2019.
Adial Pharmaceuticals engages CRO to begin Phase 3 clinical trials of AD04
Recommended For You
More Trending News
About ADIL Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
ADIL | - | - |
Adial Pharmaceuticals, Inc. |